CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+19.3%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.75B
AUM Growth
+$1.75B
(+4.4%)
Cap. Flow
-$159M
Cap. Flow
% of AUM
-9.12%
Top 10 Holdings %
Top 10 Hldgs %
69.04%
Holding
38
New
9
Increased
6
Reduced
9
Closed
8
Top Buys
| 1 |
BLUE
bluebird bio
BLUE
|
$77.8M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
$67.1M |
| 3 |
Viatris
VTRS
|
$51.5M |
| 4 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$39.3M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
$32.5M |
Top Sells
| 1 |
AbbVie
ABBV
|
$91.4M |
| 2 |
Ventas
VTR
|
$87.1M |
| 3 |
HCA Healthcare
HCA
|
$76.4M |
| 4 |
Biogen
BIIB
|
$63.3M |
| 5 |
Sarepta Therapeutics
SRPT
|
$52.1M |
Sector Composition
| 1 | Healthcare | 86.98% |
| 2 | Technology | 10.19% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHNG
1
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $178M | 10.19% | 15,900,000 +2,900,000 | +22% | +$32.5M |
|
|
2
Viatris
VTRS
$12.3B
| $177M | 10.12% | 11,000,000 +3,205,000 | +41% | +$51.5M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $157M | 8.99% | 1,400,000 -250,000 | -15% | -$28.1M |
|
4
Alkermes
ALKS
$4.78B
| $141M | 8.05% | 7,250,000 +1,200,000 | +20% | +$23.3M |
|
5
Perrigo
PRGO
$3.27B
| $124M | 7.11% | 2,250,000 +250,000 | +13% | +$13.8M |
|
6
GSK
GSK
$79.9B
| $122M | 7% | 3,000,000 | – | – |
|
7
Universal Health Services
UHS
$11.6B
| $92.9M | 5.31% | 1,000,000 -125,000 | -11% | -$11.6M |
|
|
BLUE
8
DELISTED
bluebird bio
BLUE
| $77.8M | 4.45% | +1,275,000 | New | +$77.8M |
|
9
Nektar Therapeutics
NKTR
$568M
| $69.5M | 3.98% | 3,000,000 | – | – |
|
|
10
Ironwood Pharmaceuticals
IRWD
$214M
| $67.1M | 3.84% | +6,500,000 | New | +$67.1M |
|
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $64.1M | 3.67% | 400,000 -325,000 | -45% | -$52.1M |
|
12
Ascendis Pharma
ASND
$11.8B
| $51.8M | 2.96% | 350,000 -186,710 | -35% | -$27.6M |
|
13
Myriad Genetics
MYGN
$593M
| $45.4M | 2.6% | 4,000,000 +1,650,000 | +70% | +$18.7M |
|
14
Brookdale Senior Living
BKD
$1.83B
| $44.3M | 2.53% | 15,000,000 -2,000,000 | -12% | -$5.9M |
|
|
15
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $39.3M | 2.25% | +2,200,000 | New | +$39.3M |
|
16
Collegium Pharmaceutical
COLL
$1.22B
| $35M | 2% | 2,000,000 | – | – |
|
|
AMAG
17
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $33.6M | 1.92% | 4,390,000 | – | – |
|
18
Glaukos
GKOS
$5.5B
| $28M | 1.6% | +730,000 | New | +$28M |
|
19
Puma Biotechnology
PBYI
$254M
| $25M | 1.43% | 2,400,000 +450,000 | +23% | +$4.69M |
|
20
Teva Pharmaceuticals
TEVA
$21.1B
| $24.7M | 1.41% | +2,000,000 | New | +$24.7M |
|
|
TECX
21
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $23.6M | 1.35% | 1,350,000 | – | – |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $21.8M | 1.25% | +525,000 | New | +$21.8M |
|
23
Atara Biotherapeutics
ATRA
$84.6M
| $20.4M | 1.17% | 1,400,000 -78,753 | -5% | -$1.15M |
|
24
Immunovant
IMVT
$2.56B
| $19.5M | 1.11% | +800,000 | New | +$19.5M |
|
|
TBIO
25
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $17.9M | 1.03% | 1,000,000 -765,000 | -43% | -$13.7M |
|